nivolumab
FDA Approves Subcutaneous Formulation of Bristol Myers’ Opdivo for Solid Tumor Indications
FDA approval, subcutaneous Opdivo, Bristol Myers Squibb, cancer treatment, immunotherapy, nivolumab, hyaluronidase
FDA Approves BMS’ Opdivo for Perioperative Treatment of Resectable Non-Small Cell Lung Cancer
Opdivo (nivolumab), Perioperative treatment, Resectable non-small cell lung cancer (NSCLC), FDA approval, CheckMate-77T trial, Neoadjuvant and adjuvant therapy
FDA Considers Restricting PD-1 Drugs in Stomach and Esophageal Cancers Based on PD-L1 Expression
PD-1 drugs, stomach cancer, esophageal cancer, PD-L1 expression, FDA restrictions, pembrolizumab, nivolumab, tislelizumab
AVEO Oncology’s Fotivda Combo Fails to Meet Primary Endpoint in Phase III Renal Cell Carcinoma Study
AVEO Oncology, Fotivda, tivozanib, renal cell carcinoma, Phase III clinical trial, TiNivo-2 study, nivolumab, Opdivo, kidney cancer